Clinical trial
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
NCT00238121 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00238121 |
|---|---|
| Title | Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer |
| Official title | A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Uterine Sarcoma, Stage III Uterine Sarcoma, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma |
| Intervention type | Drug |
| Interventions | sorafenib tosylate |
| Enrollment | 56 |
| Start date | Feb 1, 2005 |
| Primary completion | Jul 1, 2010 |
| Completion | Jul 1, 2010 |
| First posted | Oct 13, 2005 |
| Last update posted | Nov 20, 2015 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: